Table 3.
Summarizing the Current Trials and Targets of BiTEs, DARTs, BiKEs, and TriKEs.
| Target | Drug (Antibody Construct) | Patient Population | NCT | Phase |
|---|---|---|---|---|
| CD33 | AMV564 (CD3 × CD33 bispecific antibody) | R/R AML | NCT03144245 | 1 |
| AMG673 (CD3 × CD33 bispecific antibody) | R/R AML | NCT03224819 | 1 | |
| GEM333 (CD3 × CD33 bispecific antibody) | R/R AML | NCT03516760 | 1 | |
| JNJ-67571244 (CD3 × CD33 bispecific antibody) | R/R AML, MDS | NCT03915379 | 1 | |
| AMG330 (CD3 × CD33 bispecific antibody) | R/R AML, Minimal Residual Disease Positive AML, MDS | NCT02520427 | 1 | |
| AMV564 (CD3 × CD33 bispecific antibody) | MDS | NCT03516591 | 1 | |
| CD123 | JNJ-63709178 (CD3 × CD123 bispecific antibody) | R/R AML | NCT02715011 | 1 |
| APVO436 (CD3 × CD123 bispecific antibody) | R/R AML, MDS | NCT03647800 | 1 | |
| MGD006 (CD3 × CD123 DART) | R/R AML, MDS | NCT02152956 | 1 and 2 | |
| SAR440234 (CD3 × CD123 bispecific antibody) | R/R AML, MDS, B-ALL | NCT03594955 | 1 and 2 | |
| XmAb14045 (CD3 × CD123 bispecific antibody) | CD123 Expressing hematologic malignancies | NCT02730312 | 1 | |
| CD16/CD33 | GTB-3550 (CD16/IL-15/CD33 TriKE) | R/R AML, MDS, Advanced Systemic Mastocytosis | NCT03214666 | 1 and 2 |
| CD135 | AMG427 (CD3 × CD135(FLT3) bispecific antibody) | R/R AML | NCT03541369 | 1 |
| CLEC12A | MCLA-117 (CD3 × CLEC12A bispecific antibody) | R/R AML and newly diagnosed elderly AML | NCT03038230 | 1 |